DarioHealth stock reports Q2 revenue of USD 5.2 million

Published on 10/04/2026 at 22:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DarioHealth stock posted a Q2 net loss of USD 7.9 million on August 11, 2026. A New Jersey contract covers 1.5 million lives and starts revenue in Q1 2027.

DRIO, US23725P3082, Illustration mit AI erstellt.

DarioHealth stock (ISIN US23725P3082) closed at USD 6.16 on Nasdaq on October 1, 2026, down 6.95 percent from the prior session. The central company story is its second-quarter transition toward recurring business, with revenue of USD 5.2 million and a net loss of USD 7.9 million.

Q2 revenue fell as margins improved

According to the Yahoo Finance transcript dated August 11, 2026, second-quarter revenue was USD 5.2 million, compared with USD 5.6 million in Q1 2026 and USD 5.4 million in Q2 2025.

The same call showed a different trend in profitability. Gross margin rose to 62 percent from 57 percent in the prior quarter and 55 percent a year earlier, while the USD 7.9 million net loss was 39 percent lower than the USD 13.0 million loss in Q2 2025.

Contract adds 1.5 million covered lives

On September 17, 2026, DarioHealth announced a New Jersey health-plan contract covering 1.5 million lives through its Amwell channel partnership, as reported by Yahoo Finance. The program is expected to begin generating revenue in Q1 2027.

The contract expands Dario's cardiometabolic and provider-backed care offering across self-funded employer groups. It is the third large state health plan signed through Amwell in the past 12 months, placing commercial execution alongside the quarter's margin improvement.

Analyst targets stay above the stock

MarketBeat reported a Hold consensus from four analysts, with two Buy ratings, one Hold rating and one Sell rating, plus an average price target of USD 10.00. The target stands 62.3 percent above the October 1 price of USD 6.16.

MarketBeat also reported that TD Cowen cut its target from USD 11.00 to USD 8.00 on August 12, 2026, while Alliance Global Partners initiated coverage with a Buy rating and a USD 12.00 target on August 19, 2026.

DarioHealth stock closes at USD 6.16

The October 1 Nasdaq close of USD 6.16 gives DarioHealth a concrete market reference after the stock's 6.95 percent decline. The next earnings date listed by Investing.com is November 16, 2026.